1

CHAPTER 1: GENERAL INTRODUCTION
Hexokinase in Metabolism
The first step in the metabolism of glucose (Glc) is usually phosphorylation catalyzed by hexokinase (ATP: D-hexose 6-phosphate transferase, EC 2.7.1.1) to produce glucose-6-phosphate (Glc-6-P). Selective expression of isozymic forms of hexokinase, differing in catalytic and regulatory properties as well as subcellular localization, is likely to be an important factor in determining the pattern of Glc metabolism in mammalian tissues/cells (1) .
Mammals have four types of isozymes for hexokinase: I, II, III, IV. Hexokinase I (HKI), which is also known as brain hexokinase regulates the glucose metabolism in brain tissues, kidney and red blood cells (2) . Hexokinase I, II and III have the molecular weights of approximately 100 kDa (3), which has both C-and N-terminal halves with significant levels of sequence identity to each other and also to the yeast hexokinase (4) . Similarities between mammalian isozymes evidently originate from the duplication and fusion of a primordial hexokinase gene similar to that of yeast hexokinase (5) . According to Katzen and Schimke, the properties of the different types of hexokinase do not vary much from tissue to tissue, but are present in different amounts depending on age, stability and nutritional factors (3) . There are number of ligands that inhibit brain hexokinase, but Glc-6-P, which is also the product of glucose phosphorylation, is probably the main physiological inhibitor (6) . Glc-6-P inhibits brain hexokinase by binding to either the C-or N-terminal halves with high affinity (7, 8) .
Under normal physiological conditions, however, inorganic orthophosphate (Pi) seems to alleviate the inhibition caused by the Glc-6-P in brain hexokinase (9) . Pi binds to the Nterminal half of the HKI and lessens Glc-6-P inhibition by an allosteric mechanism that couples both halves of the enzyme (10, 11) . At the higher concentration, Pi inhibits HKI by binding to the active site (12) . Formation of the Glc-6-P by hexokinase targets glucose to alternative metabolic pathways: glycolysis, glycogen synthesis and the pentose phosphate pathway (1) (Fig. 1 ). These metabolic pathways are associated to different extents with various organs of the body and with the different isozymes of mammalian hexokinase. Type I hexokinase binds to mitochondria through interaction with porin, the protein that forms channels through which metabolites traverse the outer mitochondrial membrane (OMM). The Type II isozyme also binds to the mitochondria. Hexokinase Type III and Type IV do not bind to the mitochondria due to the absence of hydrophobic N-terminal residues. Thus these isozymes might be associated with metabolic pathways other than glycolysis (1). 
Structure of Hexokinase
The structure of recombinant human brain hexokinase (Fig. 2) has been solved by methods of X-ray crystallography (13) (14) (15) (16) (17) (18) (19) . Brain hexokinase is a functional monomeric enzyme in solution; however it exists as a dimer in the crystal, with Glc/Glc-6-P or Glc/Pi binding in both N-and C-halves (15, 16) . In the dimer, HKI subunits align head-to-tail; with two fold rotational symmetry such that the N-terminal domain of one subunit interacts with C-terminal domain of other subunit (13, (15) (16) (17) (18) . The monomeric structure of an engineered monomer of hexokinase I adopts a rod-like conformation similar to that for a subunit in other crystalline dimers (14, 19) .
Hexokinase in its monomeric form has two structurally similar halves: N-terminal and Cterminal domains which are separated by a transition helix which extends from residues 448
to 475 (14) (15) (16) (17) (18) (19) (20) . Each half has a large domain (residues 13-74, 210-447 in N-terminal half and residues 466-522, 658-895 in the C-terminal half); and small domain (residues 75-209, 448-465 in N-terminal half and residues 523-657, 896-913 in C-terminal half) (19) . The relative position of the two domains in the C-terminal half in HKI defines two conformational states for HKI, open and closed. The N-terminal half however has been observed in only a closed conformation. Moreover, the N-terminal half evidently is more stable than the C-terminal half, as the C-terminal half folds before the N-terminal half (20, 21) .
Although resembling the catalytically-active C-terminal half, the N-terminal half of the HKI is inactive. Nonetheless, the N-terminal half has a binding pocket for the Glc and Glc-6-P which is nearly identical to that of the C-terminal half (16) . Crystal structures reveal the high affinity binding site for Pi, which overlaps the binding site of the 6-phosphoryl group of the Glc-6-P, is at the N-terminal half (15, 16) . The conformation of the N-terminal half in its Pi and Glc-6-P complexed structures differs only in the conformation of loop 445-450 at the N-terminal end of the transition helix (19 
Mitochondrial Binding of Hexokinase I
Hexokinase I and II have the ability to bind to the outer mitochondrial membrane (OMM), a property which requires the first 15 residues of its N-terminus (22) (23) (24) (25) . Xie and Wilson (25) proposed that the hydrophobic tail is helical and Mulichak et al. (17) confirmed a helical structure by a crystal structure determination of the native rat-brain enzyme. Hexokinase I association with the OMM allows preferential access to newly formed mitochondrial ATP (22) , but perhaps more importantly the interaction with the voltage-dependent anion channel (VDAC) putatively is arrests mitochondrially-linked apoptosis (26, 27) .
The N-terminal sequence of the rat brain hexokinase was determined to be
where X is blocking group at the N-terminal methionine. The chemical identity of the blocking group is unknown, but generally assumed an N-acetyl group. Elimination of the Nterminal segment by endogenous proteases in crude brain extracts eliminates mitochondrial binding (28) . N-acetylation of the methionine is the norm rather than the exception for many cellular proteins and hence, finding a blocked N-terminus on the brain hexokinase is not unexpected (29, 30) . The N-terminal segment of the hexokinase is readily accessible at the surface of the hexokinase. Hence, it is highly susceptible to proteolytic modification (28) . 
Glucose-6-phosphate Release of Mitochondrially Bound Hexokinase
Glc-6-P is not only a potent inhibitor of brain hexokinase at physiological concentrations, but it can also release the enzyme from the brain mitochondria (22) . HKI-release of Glc-6-P from mitochondria may be the first step in an enzyme degradation pathway (22) and/or a process linked to apoptosis (33) (34) (35) (36) . Fromm and Zewe (37) demonstrated that Glc-6-P is a competitive inhibitor of ATP and linear noncompetitive inhibitor of glucose. Skaff, et al. (38) in 2005 showed that Glc-6-P binding to the N-terminal half is responsible for the release of recombinant human brain hexokinase from the mitochondrion. It has been shown that Glc-6-P induces conformational change in the N-terminal half of the HKI that consequently releases the enzyme from the mitochondrial membrane. The exact understanding of the presumed conformational change has been elusive, as crystal structure reveal Glc-6-P and Pi bound N-terminal halves have the same conformation but for a span of five residues preceding the transition helix. Mehyar (39) in 2011 found the residues of the N-terminal helix critical to binding with the mitochondrial. Mutations A4L, A8L and Q5P individually caused ten-fold decreases in HKI binding to mitochondria relative to the wild-type enzyme (39) . Residues A4 and A8, which define a contiguous surface, does not tolerate large hydrophobic side chains (39) .
Hypothesis
Some studies suggest that hexokinase binding to the mitochondria is determined by the hydrophobicity of the N-terminal tail (40, 41) . Co-localization of brain hexokinase with the VDAC at the OMM suggests more complex and specific interactions than the general hydrophobic interactions with the lipid (26) . Chymotrypsin removes the hydrophobic tail on the N-terminal domain and thus prevents the binding of hexokinase to the mitochondria (22, 28, 31) implying the importance of the first 12-residues in the N-terminal domain. It was also discovered that certain residues among those first 12 residues are critical for hexokinase 
Thesis Organization
This thesis has three chapters. Chapter 1 is a general introduction of HKI providing background information related to structure, properties of metabolite regulation and mitochondrial binding, as well as the goal of research, and a brief summary of the outcome of experimental work. Chapter 2 presents the experimental work in detail, and represents a manuscript for publication in a peer-reviewed journal. Chapter 3 provides a conclusion and is far less important. Met1 would define a contiguous surface with Ala4 and Ala8, assuming an α-helical structure for these N-terminal residues. Recombinant human HKI, as is the case for the native enzyme from rat, cannot be sequenced due to a blocked amino terminus.
Mutation of Ile2 to threonine, enables an Escherichia coli expression system to cleave the isozymes from I to III show extensive sequence similarity of about 50% and structure similarity (5) . These sequence similarities between mammalian isoenzymes evidently originate from the duplication and fusion of a primordial hexokinase gene similar to that of Type IV hexokinase and yeast hexokinase (6) . The properties of a hexokinase type does not differ vary from one tissue to another, but the amount each isozyme differs depending on age and nutritional factors (7). Hexokinase I (HKI), also known as brain hexokinase, can be inhibited by the number of ligands including Glc-6-P which is also the product of the reaction (4). Glc-6-P inhibits brain hexokinase catalysis by binding to either the C-or Nterminal halves with high affinity (8, 9) . Inorganic orthophosphate (Pi) under normal physiological conditions can decrease the inhibition caused by the Glc-6-P (10) through an allosteric mechanism that couples both halves of the enzyme (11, 12) .
Even though HKI is a dimer in crystals (13, 14) , the monomer is the dominant form in solution. HKI has two structurally similar halves (N-terminal and C-terminal halves), separated by a transition helix (residues 448 to 475) (14) (15) (16) (17) (18) (19) (20) . The N-terminal half of the brain hexokinase is catalytically inactive, but contains a binding pocket for Glc and Glc-6-P which is nearly identical to that of the C-terminal half (14) . The crystal structure also reveals that N-terminal half has a high-affinity binding site for the Pi which overlaps the binding site for the 6-phosphoryl group of Glc-6-P (14, 16). Glc-6-P, however, inhibits brain hexokinase by binding to either half of the enzyme (21).
Hexokinases I and II bind to mitochondria. The binding property requires the first 15 residues of the polypeptide. None of the residues have formal electrostatic charge, and the amino terminus is blocked for HKI isolated from rat brain (22) (23) (24) (25) . Xie and Wilson (25) proposed that the N-terminal segment is in an α-helical conformation, and Mulichak et al. 
Construction of Wild-type Hexokinase and Mutant Plasmids-Human brain hexokinase
(HKI) has been cloned into pET-11a as reported in a previous study (31) 
Expression and Purification of Wild-type and Mutant Hexokinase-Wild-type or mutant
pET-211a-HKI plasmids were transformed into E. coli strain BL21 (DE3). Expression and purification of HKI constructs here followed protocols in the literature (31) . The concentration of the protein was measure by the Bradford method with bovine serum albumin as a standard. Protein purity was determined by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE).
Pig Liver Mitochondria Isolation-Fresh pig livers were obtained from the Meat Laboratory of Iowa State University. Mitochondrial purification is described (32) with modifications as discussed in (1) . Both outer mitochondrial membrane (OMM) and inner mitochondrial membrane (IMM) integrities were measured as described previously (33, 34) . Mitochondria were stored at -80°C in the presence of storage buffer.
The HKI Activity Assay-Hexokianse I activity was measured using the glucose-6-phosphate dehydrogenase (G6PDH)-coupled spectrophotometric assay at pH 8. NADPH production was monitored at wavelength of 340 nm. Assays were initiated by the addition of enzyme and linear progress curves monitored for 2 minutes. Slopes of progress curves determined initial rates in µmole/min. The capacity of the coupling enzymes was verified by observing two-fold increase in velocity with a doubling of added hexokinase.
Fits of the Michaelis-Menten model to initial velocity data used the software GraFit (35).
Hexokinase Mitochondrial Binding-Purified HKI was dialyzed twice against mitochondrial-binding buffer (250 mM sucrose, 5 mM Glc, 50 mM NaCl, 5 mM MgCl 2 and 50 mM HEPES, pH 7.4), and then diluted to 2 mg/ml using the same buffer. Thirty mg wet weight of mitochondrion, thawed on ice, was suspended in 1 mL of mitochondrial-binding buffer, and then collected by centrifugation at 11000 x g for 5 minutes at 4°C. Suspension and centrifugation steps were repeated twice. The pellet was suspended in 1 ml of mitochondrial-binding buffer with added HKI (2 mg/ml), protease cocktail inhibitor (0.25 mg/ml) and PMSF (1 mM). After 30 minutes on ice, the mixture of HKI and mitochondria was centrifuged at 11000 x g for 5 minutes. Unbound HKI remained in the supernatant fluid and was separated from the pellet. Pelleted mitochondria were suspended in mitochondrialbinding buffer, less the MgCl 2 , NaCl, and glucose, and centrifuged again. This was step was twice-repeated.
N-terminal Sequencing-
A thin piece of polyvinylidene fluoride (PVDF) was activated using 100% methanol. PVDF membrane was washed a couple of times with dionizeddistilled water and dipped into 2 mg/ml hexokinase overnight at 4°C. The PVDF was taken out of the protein solution and rinsed sparingly with water before submitting to the Protein Facility at Iowa State University.
Results
Rationale for HKI mutants-The N-terminal 15 residues forms an α-helix. As shown previously by Mehyar (27) , mutations individually of Ala4 and Ala8 to leucine eliminate hexokinase binding to the mitochondrion. Ala4 and Ala8 lie on the same face of the helix, and in a recent model that face is in contact with the outer surface of the β-barrel of VDAC (27) . Met1 extends the surface defined by Ala4 and Ala8. 
Kinetics of Wild-type and Mutant
Hexokinases-The kinetic parameters of the different mutants are comparable to those of wild-type HKI ( Table 1) . As the N-terminal segment can be remove entirely without influencing catalysis or metabolite regulatory properties of HKI, the lack of any effect on basic kinetic properties is an expected outcome. Mitochondrial Integrity-The outer membrane integrity of isolated mitochondrion was 90%
as shown by the cytochrome c oxidase activity assay (data not shown). Inner membrane integrity was confirmed by mitochondrial uptake of cationic carbocyanide dye JC-1 (data not shown).
Mitochondrial Binding of Wild-type and Mutant Hexokinases-The isolated mitochondria
are devoid of native hexokinase activity. Fig. 1 shows that the binding response curve of wild-type hexokinase from my result is comparable to the wild-type hexokinase binding experiment performed by Mehyar (27) . Fig.1 and Fig. 2 shows that with the increase in the hexokinase concentration, its binding to the mitochondria increase in most of the purified proteins.
Scheme I represents the simplest equilibrium model that accounts for the binding of the wildtype and mutant hexokinase to the mitochondria.
Scheme I
In Scheme I, K 1 represents an association constant for the binding of the HKI construct (represented by E) to specific mitochondrial binding sites Q. As demonstrated by the previous work, non-specific binding to the mitochondrion by HKI does not occur at the significant levels. The ratio of enzyme bound to the total enzyme, E o, is as follows
The concentration of the free specific mitochondrial sites Q is itself a function of the concentration of the enzyme. Algebraic manipulation of the equilibrium expression in the Scheme I and the relationship for mass conservation of total enzyme E o and total specific sites Q o gives a quadratic relationship in E:
where a=K 1 There is no indication that HKI requires a blocked N-terminus in order to bind to the mitochondrion.
The acetyl-linked N-terminal methionine is critical for some protein-protein interactions (40) .
In such cases, N-acetyl methionine can be without formal charge in a hydrophobic environment, whereas a positively charged free amino group would be disfavored (40) .
Evidently a blocked N-terminus for HKI is not essential for mitochondrial association, but instead could eliminate uncontrolled chemistry. A membrane-buried amino group would necessarily be neutral (unprotonated) and reactive as a nucleophile. Over time, an unblocked N-terminus could react indiscriminately with electrophilic centers in other membraneassociated proteins. The resulting cross-linked proteins would contribute to a pool of damaged proteins that could interfere with normal regulatory processes.
Hydrophobic surfaces contribute to the interaction of HKI with the mitochondrion (41), but the specific binding of the brain hexokinase to only mitochondria cannot be explained by a nonspecific hydrophobic interaction with the lipid bilayer (25) . Indeed, mutations of Ala4 and Ala8 to leucine eliminate HKI binding to mitochondria, indicating a specific proteinprotein interaction that targets HKI to the outer membrane of the mitochondrion (27) . Coarse grain modeling (Yang Gao, and Richard Honzatko, unpublished) indicates that the surface defined by Ala4 and Ala8 is spatially contiguous and has a preferred (low energy) placement on the surface of the β-barrel of VDAC. In that coarse-grain model of a VDAC-HKI complex, the center of mass of the N-terminal half of HKI is over the pore of VDAC, in proximity to residues that are significant to high affinity HKI-mitochondrial binding. The model indicates that Met1 and to a lesser extent Ile2 could also participate in hexokinasemitochondrial interactions. To investigate the role of Ile2 and Met1 in binding interactions, residues (Met-Ile-Ala-Ala)
were introduced at the N-terminus, duplicating the first four residues of wild-type HKI. The addition of four residues did not alter binding affinity for the mitochondrion relative to wildtype enzyme. The mutation of Ile2 to threonine of this elongated construct (MIAA-Ile2Thr) has little effect on HKI-mitochondrial binding; however, the mutation of Met1 to leucine (MIAA-Met1Leu) causes a significant reduction to binding affinity. This result is consistent with the current course-grain model in that Met1 extends the contiguous surface defined by Ala4 and Ala8 (Fig. 5) . Moreover, as leucine is a conservative replacement for methionine that often does not cause a significant change in protein conformation, the observation of a significant effect here indicates a highly specific level of recognition of the side chain of methionine by the interacting partner.
CHAPTER 3: GENERAL CONCLUSIONS
The hydrophobicity of 15 N-terminal residues does not explain the specificity of HKI binding to the outer membrane of the mitochondrion. Selective mutations among the first 15 residues in past investigations indicated the significance of Ala4 and Ala8 in the interaction, but the significance of Met1, which is adjacent to Ala4 assuming a helical structure, was 
